A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma (MajesTEC-2)
A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Sponsor: Janssen Research & Development, LLC
Listed as NCT04722146, this PHASE1 trial focuses on Multiple Myeloma and remains ongoing. Sponsored by Janssen Research & Development, LLC, it has been updated 50 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
50 versions recorded-
Mar 2026 — Present [monthly]
Active Not Recruiting PHASE1
-
Feb 2026 — Mar 2026 [monthly]
Active Not Recruiting PHASE1
-
Jan 2026 — Feb 2026 [monthly]
Active Not Recruiting PHASE1
-
Dec 2025 — Jan 2026 [monthly]
Active Not Recruiting PHASE1
-
Nov 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE1
▶ Show 45 earlier versions
-
Oct 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE1
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE1
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE1
-
Jun 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE1
-
May 2025 — Jun 2025 [monthly]
Active Not Recruiting PHASE1
-
Nov 2024 — May 2025 [monthly]
Active Not Recruiting PHASE1
-
Oct 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE1
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
-
May 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE1
-
Apr 2024 — May 2024 [monthly]
Active Not Recruiting PHASE1
-
Mar 2024 — Apr 2024 [monthly]
Active Not Recruiting PHASE1
-
Feb 2024 — Mar 2024 [monthly]
Active Not Recruiting PHASE1
-
Jan 2024 — Feb 2024 [monthly]
Active Not Recruiting PHASE1
-
Dec 2023 — Jan 2024 [monthly]
Active Not Recruiting PHASE1
-
Nov 2023 — Dec 2023 [monthly]
Active Not Recruiting PHASE1
-
Oct 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE1
-
Sep 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE1
-
Aug 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE1
-
Jun 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE1
-
May 2023 — Jun 2023 [monthly]
Active Not Recruiting PHASE1
-
Apr 2023 — May 2023 [monthly]
Active Not Recruiting PHASE1
-
Mar 2023 — Apr 2023 [monthly]
Active Not Recruiting PHASE1
-
Feb 2023 — Mar 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE1
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE1
-
Nov 2022 — Dec 2022 [monthly]
Recruiting PHASE1
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE1
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE1
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE1
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE1
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE1
-
Feb 2022 — Apr 2022 [monthly]
Recruiting PHASE1
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE1
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE1
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE1
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE1
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE1
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE1
-
Apr 2021 — May 2021 [monthly]
Recruiting PHASE1
-
Mar 2021 — Apr 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Feb 2021 — Mar 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Janssen Research & Development, LLC
For direct contact, visit the study record on ClinicalTrials.gov .